Heligenics was converted to a C corporation in late 2019. We started with just two employees and a team of advisors. We now have 8 research and administration employees, 6 sales consultants, and 3 board members. We successfully closed some deals and are seeking new customers and partners for this year's production queue. We recently moved from our Las Vegas startup building to a class A research facility within the Roseman University Summerlin Campus.

​

                     

                       Our Mission                       

 

To prevent disease and heal patients afflicted with illness through genomics.

​

​

Our Approach

Based on the GigaAssay technology developed at the University of Nevada Las Vegas in the Schiller Laboratory of Applied Bioinformatics, our GigaAssay is a massively parallel biological platform that can simultaneously measure how tens of thousands of genetic variants or other sequence variables affect a molecular function or a cell process. To date, there are no other established high-throughput assays that assess biological function.

​

The GigaAssay produces functional genomics data that can be licensed and used for prevention-based approaches, diagnostics, drug selection and discovery of new biologic drugs. Additionally, for developing new drug therapies or redesigning clinical trials for drugs that have failed a trial due to poor efficacy or safety. Heligenics products will transform the medical industry.